The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells

Abstract excerpt

Third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), including osimertinib, an irreversible EGFR-TKI, are important treatments for non-small cell lung cancer with EGFR-TKI sensitizing or EGFR T790M resistance mutations. While patients treated with osimertinib show clinical benefit, disease progression and drug resistance are common. Emergence of de novo acquired resistance from a drug tolerant persister...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Hippo pathway signaling and YAP/TAZ
• Share to Lung Cancer Treatments and Mutations
• Share to Protein Degradation and Inhibitors